However, BRQ plus anti–PD-1 mAb significantly reduced primary tumor growth in both tumor models, and the therapeutic efficacy of the combination regimen versus the single-agent treatments was synergistic (Figure 4, B and C, and Supplemental Figure 4, A and B). This evidence concerns the gene PDCD1 and neoplasm.